Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 5th Annual Conference on Stroke and Neurological Disorders Amsterdam, Netherlands.

Day 2 :

Keynote Forum

Tayfun Uzbay

Uskudar University, Turkey

Keynote: Genoplasticity, brain and neuropsychiatric disorders

Time : 9:30am to 10:15am

Conference Series Stroke Meet 2018 International Conference Keynote Speaker Tayfun Uzbay photo
Biography:

Tayfun Uzbay has completed his PhD at the age of 32 years from Gulhane Medical School in Ankara and postdoctoral studies from University of North Texas, Department of Pharmacology and Neuroscience in USA and University of Cagliari, Department of Toxicology in Italy. He is the director of Neuropsychopharmacology Application and Research Center (NPARC) at Üsküdar University in İstanbul. Professor Uzbay is a founder of Psychopharmacology Research Unit in Turkey. His research studies have focused on Behavioral Neuroscience. He has patents of some molecules for schizophrenia treatment. He has published more than 200 papers in reputed journals and citations more than 3500.

Abstract:

One of the most intriguing and fundamental properties of brain function is the ability to sustain long-term changes in patterns of neuronal activity. This concept, called neuroplasticity or brain plasticity, refers to the ability of adaptation and change-ability of brain within the time. Sometimes the reorganization or re-adaptation mediates vital and important physiological events such as learning and memory by LTP; but sometimes, especially under internal or external heavy stressful conditions, the statement is called as contra-adaptation and it is responsible for several neuropsychiatric diseases.
Neuroplasticity is a continuous process in reaction to neuronal activity and neuron injury, death, and genesis, which involves modulation of structural and functional processes of axons, dendrites and synapses. Elements of signal transduction cascade (SDC) between the neurons include in neurotransmitters, receptors, G proteins, second messengers, protein kinases, and transcription factors. If anyone of these elements has failure, pathological conditions (contra-adaptation) occur in brain. Each step of neurotransmission is influenced by changes in genes and DNA in SDC. In fact, neuroplasticity is a result of adaptive genomic changes in SDC and it is a product of gene plasticity or genoplasticity. However, the term genoplasticity does not frequently used in literature. Today, we do not have any radical solutions in treatment of important neuropsychiatric diseases such as autism, schizophrenia, addiction and Alzheimer yet. Some external and internal factors may change task definition of neurons by causing genomic changes and occurring mutant or terrorist neurons may cause severe brain disorders. We should also approach to neuropsychiatric diseases in aspect to genoplasticity.

Conference Series Stroke Meet 2018 International Conference Keynote Speaker Yavuz Selim Silay photo
Biography:

Yavuz Selim SILAY is the chairman of Istanbul Consulting Group. ICG(Istanbul Consulting Group) was founded in 2013 and provided guidance to the Turkish ministry of health as part of a World Bank project.Yavuz is currently the Co-Founder of BioCube İstanbul Bioentrepreneurship & Innovation Center and Corporate Communication Director of Sumitomo Group/ Expel İlaç Archem Diagnostices Endmed and Diagen. He previously managed the largest distributor of Siemens Healthcare in Turkey managing 250 employees and director of Avcılar Hospital R&D Center, Chief Medical Officer of Lifematrix GmbH. Previously he worked as the Market Access & Health Policy Director for AIFD in Turkey. Yavuz previously worked as the Vice President of Ipsen pharmaceutical and Director of Teva pharmaceutical in USA managing large clinical trials as well as Investigator Initiated Trials and developing relationships with Key Opinion Leaders. Previously, Yavuz was the Associate Director at KV Pharmaceuticals and Director in Clinical Development department at Forest Laboratories. Yavuz earned his MD from the Faculty of Medicine, University of Ankara in Ankara, Turkey. He completed a clinical internship at Baylor College of Medicine in Houston, followed by continued research training at The University of Texas MD Anderson Cancer Center in Houston. He recently completed his Executive MBA at the Olin Business School at Washington University in St. Louis. Yavuz currently resides with his wife Dr. Kamile Sılay and their two daughters and one son in Ankara,Turkey.

Abstract:

Pharmaceutical, Biotech and Medical Device companies are constantly evaluating how decisions at the US ,Europe, Turkey and emerging markets are taken at the federal and state level and how it will impact provider and patient access and coverage to their therapies. To gain these critical insights, Government Affairs & Medical affairs teams require speaking with those on the frontlines of healthcare delivery - physicians, allied healthcare professionals, payers, and patients. New generation government engagement and commercial diplomacy approach developed by ICG (Istanbul Consulting Group) will be provided with unique cases. Dr. Yavuz Selim SILAY a global leader and seasoned expert in Government engagement, Commercial Diplomacy, Corporate Communications, Government affairs & Medical Affairs will discuss how companies utilizing Government Affairs and Medical affairs teams should engage decision makers, payers,physicians and acquire these insights in a convenient, cost-effective, and compliant manner in this current changing global regulatory landscape.

  • Neuropsychiatry| Neuroprotection | Stroke Rehabilitation and Brain Hemorrhage
Location: Akdeniz 3
Speaker

Chair

Engin KN,

Saglık University, Istanbul, Turkey

Session Introduction

Engin KN

Saglık University, Istanbul, Turkey

Title: Eye-to-visual-pathway integrity of glaucomatous neurodegeneration

Time : 11:15am-11:45 am

Speaker
Biography:

Engin KN is an ophthalmologist and PhD on Biochemistry. He has a strong focus on optic nerve and his areas of interest are glaucomatous neurodegeneration, oxidative stress, neuroprotection and Vitamin E. Currently, his review article “Alpha Tocopherol: Looking beyond an antioxidant” have been cited over 90 times. Along with other academic activities, he is author of 39 publications, 7 special lectures, more than 70 presentations, and he received 6 awards. He is member of ARVO, EVER, Society of Free Radicals and Antioxidants Research (Turkey). Since 2005, he has been serving as an active member of glaucoma division of Turkish Ophthalmology Society.

Abstract:

Glaucoma represents a group of neurodegenerative diseases characterized by structural damage to the optic nerve and the slow, progressive death of retinal ganglion cells. On the other hand, impacts of glaucoma on the optic nerve (ON), corpus geniculatum lateral (CGL) and visual cortex became increasingly evident. Initial studies conducted with conventional magnetic resonance imaging (MRI) and Occipital Proton MR Spectroscopy. The techniques that the first functional and structural findings have been obtained are functional MRI (fMRI) and Diffusion-Tensor MRI (DTI), respectively. fMRI detects increased neuronal activity via changes in blood oxygenation, DTI is based on the movement principle of fluids in a plane connected to the nerve. In consecutive studies from 2006 to 2014, we aimed to evaluate the structural and functional extent of glaucomatous neurodegeneration in an attempt to develop techniques feasible for routine clinical application. In previous studies, we observed statistically significant correlation of glaucomatous neuro-degeneration between eye and visual pathways with our original techniques developed with 1,5T MRI. ON, CGL damage and cortical hypofunction were shown with DTI and fMRI, respectively. Our last cross-sectional DTI study, which is yet to be published, included 130 eyes with glaucoma. Statistically significant correlations were found between ganglion cell complex and apparent diffusion coefficient, λ1, λ┴ of optic nerves. Strategies independent from IOP, concerning the area beyond the optic nerve head, are needed in the evaluation and treatment of glaucoma. As our studies showed, clinical instruments that are largely in use are also adequate for clinical trials to reveal the glaucoma-brain connection; however, more sophisticated techniques are being developed to illuminate that relation further. A more comprehensive understanding of retro bulbar glaucomatous damage will enable us to determine more efficient diagnosis, follow-up and treatment strategies and facilitate to answer important questions which remain unknown about this disease.

Speaker
Biography:

Mufeed Al Jeady, PhD- SLP (USA 2006), Consultant Swallowing and Speech Pathologist and Rehab Programs Manager for Stroke and TBI Units . The First Certified Vital Stim Therapy Instructor in Middle East. He Has puplished many papers in a reputed journals and conducted a lot of Swallowing training courses in
Vital Stim Therapy as well as research in swallowing field and rehabilitation

Abstract:

In MBSS the following are evaluated, delay in oropharyngeal swallowing phase, closure of epiglottis, laryngeal elevation, a passage of contrast behind the epiglottis that denoting penetration, the presence of aspiration and presence residual barium after swallowing. After VitalStim therapy, all patients underwent the same assessments and also underwent a functional swallowing follow up survey months (range, 1 to 6 months) after their therapy to assess whether the improvement was worthwhile and sustained. From June 2014 to April 2016, 73 patients with dysphagia were included in our study. All the patients underwent pretherapy evaluation by speech-language pathologists, including clinical evaluation of swallowing and modified barium swallow study (MBSS). In this study 73 patients showed radiological findings denoting neurological swallowing disorders, 65 patients (89%) showed delay in oropharyngeal swallowing phase, weak laryngeal elevation found in 58 patients (79%), 68 patients (93%) showed aspiration and 70 cases (96%) showed penetration and incomplete closure of the epiglottis. Presence residual barium after swallowing within the vallecula was seen in 68 patients (93%). 52 of the 73 patients (71%) demonstrated complete improvement in their swallowing at first follow up study after VitalStim therapy. 21 of the 73 patients (29%) showed some improvement and needed another therapy sessions and in the next follow up study 15 cases showed complete improvement. However, 7 cases of the 21 patients categorized as having severe dysphagia before therapy, only 2 of 7 showed improvement, and these patients still required a feeding tube for adequate nutrition, however, the 5 of 7 showed complete improvement after another session of therapy. In conclusion, modified barium swallow is valuable in the rehabilitation of patient with swallowing disorders helps speech pathologist to identify and modify swallowing abnormalities as well as management program. VitalStim therapy is a safe and effective treatment for patients suffering with the swallowing difficulties.

Biography:

El Kaoui Habiba completed her master's degree at the age of 25 from the University ibn tofail Morocco and is currently doing her doctoral studies at the same faculty. She has published a book titled "Effects of Flaxseed on the Pathophysiology of Obesity and Behavioral Disorders following a High Fructose Diet in Wistar Rats" in an "OmniScriptum" editing group.Presenting author details.

Abstract:

Introduction: The deregulation of the energy balance by the malnutrition leads to the dysfunction of the neuro- The metabolic mechanisms but these homeostatic problems can be corrected by nutritional supplements. In this study, we investigated the effects of flaxseed on metabolism and anxiety- depressive-like disorders in high fructose-fed (23%) Wistar rat.
Methods: One-month-old female Wistar rats were divided into four groups of six rats:1. Control: (30g of standard food + 30ml of tap water), 2. Control supplemented with flaxseed (27g standard food + 7g flaxseed + 30ml tap water) 3. Fructose (30 g standard food + 23% fructose) 4. Fructose supplemented with flaxseed (23 g standard food + 7gflaxseed + 23% fructose), after two months of diet, the rats underwent a battery of tests to evaluate the affective behavior (Open Field, Elevated Plus Maze and Forced Swimming Test) and biochemical analyzes of glucose, cholesterol and triglycerides
Results: High fructose diet inducesadverse metabolic effects (increases blood sugar, cholesterol, triglycerides) and behavioral ones(depression). Forflaxseed, it does not correct anxiety, but decreases depression-like and metabolic disorders.
Conclusion: Our results suggest that a high fructose diet induces metabolic and behavioral dysfunctions. Flaxseeds have
improved these conditions.

Speaker
Biography:

Soma Sengupta is a clinician-scientist, board certified in neurology and neuro-oncology, trained at the University of Cambridge (UK) and the Harvard hospitals
(Boston, MA, USA). She is actively involved in caring for patients with brain cancers at the Winship Cancer Institute, Emory University. She initiates and participates in clinical trials, and runs a translational neuro-oncology laboratory to develop targeted therapeutic strategies to treat brain cancers as well as cancers outside the central nervous system.

Abstract:

The pediatric brain cancer medulloblastoma is comprised of four molecular subgroups. Group 3 subgroup medulloblastoma patients have the highest rates of relapse and metastasis and a 20% survival rate after standard-of-care. Our analysis of gene expression of 763 medulloblastoma tumors reveals that group 3 patient tumors share high subgroup-specific and correlative expression of GABR genes GABRA5, GABRB3 and GABRG2 and 3, which code for α5, β3 and γ2 and 3 subunits, respectively, of the ionotropic γ-aminobutyric acid type A receptor (GABAAR). There are approximately 1000 functional α5-GABAARs per cell in the group 3 patient-derived cell line D283 that mediate a basal chloride-anion flux of 2x109 ions/sec. Benzodiazepines, designed to function as α5-GABAAR preferring positive allosteric modulators with psychotropic activity, can impair the viability of group 3 cells by enhancing α5-GABAAR chloride-anion flux and subtle changes in benzodiazepine structure has significant impact on potency. A particularly potent α5-GABAAR preferring benzodiazepine (‘KRM-II-08’) that emerged from our screen and shown to be non-toxic, binds to the native α5-GABAAR with IC50 and EC50 of 0.8 μM. This benzodiazepine enhances a chloride-anion flux that induces within minutes, mitochondrial membrane depolarization and fragmentation. In
response, TP53 is upregulated and p53, constitutively phosphorylated at S392, localizes to the cytoplasm. This correlates with localization of pro-apoptotic Bcl-2-associated death promoter (BAD) protein. GABR expression can serve as a diagnostic biomarker for group 3 tumors, while α5-GABAAR is a therapeutic target for benzodiazepine binding, which enhances an ionic imbalance in group 3 cells that perturbs mitochondrial function and induces a response that results in apoptosis.

Break: 13:15pm-14:15pm
Biography:

Dr. Ali Kurt a global innovation management leader and Dr.  Yavuz Selim SILAY a global physician leader and seasoned expert in Healthcare Innovation, Physician Entrepreneurship, Government engagement, Commercial Diplomacy, Corporate Communications, Government affairs & Medical Affairs will discuss how BioCube İstanbul has been established and current engagements with academicians Venture Capital and angel Investtment networks for commercializing healthcare technologies will be discussed.

 

Abstract:

Large Pharmaceutical, Biotech and Medical Device companies are constantly evaluating how to work with universities and startup companies and utilize their know how. Istanbul Consulting Group recently worked with Istanbul Aydın University to establish a thematic program in Healthcare Bioentrepreneurship  which has taken the road with the slogan of "Towards a Bright Future", at the brightest spots of business life. Istanbul Aydın University is a city and campus university located in the center of Istanbul with its experienced academic staff who have gained a reputation for their scientific studies globally. At BioCube İstanbul several healthcare startup companies are flourishing thanks to the coordination of Technology Transfer and Project Managament offices succesful coordination on  innovation management with all key stakeholders To gain these critical insights for Thematic Management of Healthcare Bioentrepreneurship and Innovation Track in Universities and how to accelerate innovations in order to improve healthcare. We seek to empower entrepreneur academicians, doctors, other healthcare providers and with the information, resources, connections, and experience they need to commercialize their ideas, inventions and discoveries. Currrent Trends in Innovation Management in Medicine in a University Setting and the BioCube İstanbul Bioentrepreneurship and Innovation Centeras a global case for  USA Europe Turkey and Emerging Markets will be provided with unique cases.

Mohammad Alhasan

Qasseem National Hospital, Saudi Arabia

Title: Diagnosis and management of transient ischemic attack

Time : 15:15pm-15:45pm

Speaker
Biography:

Educational

2004:   Aleppo University - Medical School, Bachelor of Medicine- Syria

2009:   Syrian BOARD in Neurology Disease, Syria.

Professional:

2011 untill now : Neurology Specialist

Qaseem National Hospital – Saudi Arabia

Abstract:

This presentation reviews the diagnosis, investigation, and recommended management after a transient ischemic attack (TIA). Up to a 10% risk of recurrent stroke exists after a TIA, and up to 80% of this risk is preventable with urgent assessment and treatment. Imaging of the brain and intracranial and extracranial blood vessels using CT, CT angiography, carotid Doppler ultrasound, and MRI is an important part of the diagnostic assessment. Treatment options include anticoagulation for atrial fibrillation, carotid revascularization for symptomatic carotid artery stenosis, antiplatelet therapy, and vascular risk factor reduction strategies. TIA offers the greatest opportunity to prevent stroke that physicians encounter. A TIA should be treated as a medical emergency, as up to 80% of strokes after TIA are preventable.